IP Library Granted Patent US 9,862,698
Granted Patent B2
US 9,862,698 · App. 14/571,647 · Granted Jan 9, 2018

Indenyl compounds, pharmaceutical compositions, and medical uses thereof

Inventors: Gary A. Piazza (Daphne, AL); Xi Chen (Hoover, AL); Adam B. Keeton (Gardendale, AL); Michael R. Boyd (Orange Beach, AL)
Assignee: ADT Pharmaceuticals, Inc.
C07D317/64A61K31/341A61K31/36A61K31/40A61K31/401A61K31/44A61K31/445C07C233/58C07C235/32C07C237/20C07D207/14C07D207/337C07D211/56C07D213/24C07D213/75C07D235/30C07D307/38C07D307/52C07D307/54C07D405/12C07C2601/02C07C2602/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,862,698
App. No.
14/571,647
Granted
Jan 9, 2018
Kind
B2
Abstract

Disclosed are compounds, for example, compounds of formula I, wherein R, R 0 , R 1 -R 8 , n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

Claims (75)

1. A compound of formula (II):

wherein:

R and R 0 are independently selected from hydrogen, hydroxyl, alkyl, trifluoromethyl, amino, alkoxy and alkylamino, or R and R 0 together is double-bonded oxygen or double-bonded sulfur, or R and R 0 together is a double-bonded nitrogen bonded to hydrogen, hydroxyl, alkyl, or trifluoromethyl; n is 0, 1 or 2;

Y is hydrogen, alkyl, or trifluoromethyl, and Y′ is hydrogen, alkyl, trifluoromethyl, amino, alkylamino, or alkoxy, or Y and Y′ together is double-bonded oxygen or double-bonded sulfur, or Y and Y′ together is a double-bonded nitrogen bonded to hydrogen, hydroxyl, alkyl, or trifluoromethyl;

R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, hydroxyl, halogen, alkyl, trifluoromethyl, alkoxy, and alkylmercapto;

R 2 and R 8 are independently selected from hydrogen, alkyl, trifluoromethyl and alkoxy;

R 14 is selected from hydrogen, halogen, alkyl, trifluoromethyl, hydroxyl, formyloxy, alkylcarbonyloxy, hydroxyalkyl, aldehydo, amino, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylamino, mercapto, azido, and substituted or unsubstituted groups selected from alkylsulfinyloxy, alkylsulfonyloxy, carbamate, carbamido, alkoxycarbonyl, alkylaminocarbonyl, aminocarbonyl, and sulfonamido;

R 12 , R 13 , R 15 and R 16 are independently selected from hydrogen, halogen, alkyl, trifluoromethyl, hydroxyl, alkoxy, formyloxy, alkylcarbonyloxy, hydroxyalkyl, aldehydo, amino, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylamino, mercapto, azido, and substituted or unsubstituted groups selected from alkylsulfinyloxy, alkylsulfonyloxy, carbamate, carbamido, alkoxycarbonyl, alkylaminocarbonyl, aminocarbonyl, and sulfonamido, or

any two of R 12 , R 13 , R 14 , R 15 and R 16 form an alkylenedioxy group;

X is NR′R″, where R′ is furanyl or furanylalkyl wherein the furanyl of the furanyl or furanylalkyl is optionally substituted with one or more of halo, alkyl, trifluoromethyl, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, mercapto, alkylmercapto, carboxamido, aldehydo, cyano, oxo, alkylcarbonyloxy, and sulfonamido; and R″ is selected from hydrogen, alkyl, hydroxyalkyl, aminoalkyl, dialkylaminoalkyl, cyanoalkyl, haloalkyl, alkylcarbonylalkylcarbonyloxy, pyridyl, and COR 11 wherein R 11 is selected from hydrogen, trifluoromethyl, alkylmercapto, and aryl; or

a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. A compound of formula (II):

wherein:

R and R 0 are independently selected from hydrogen, hydroxyl, alkyl, trifluoromethyl, amino, alkoxy and alkylamino, or R and R 0 together is double-bonded oxygen or double-bonded sulfur, or R and R 0 together is a double-bonded nitrogen bonded to hydrogen, hydroxyl, alkyl, or trifluoromethyl; n is 0, 1 or 2:

Y is hydrogen, alkyl, or trifluoromethyl, and Y′ is hydrogen, alkyl, trifluoromethyl, amino, alkylamino, or alkoxy, or Y and Y′ together is double-bonded oxygen or double-bonded sulfur, or Y and Y′ together is a double-bonded nitrogen bonded to hydrogen, hydroxyl, alkyl, or trifluoromethyl;

R 1, R2 , and R 4 are independently selected from hydrogen, hydroxyl, halogen, alkyl, trifluoromethyl, alkoxy, and alkylmercapto;

R 7 and R 8 are independently selected from hydrogen, alkyl, trifluoromethyl and alkoxy;

R 12 , R 13 , R 15 and R 16 are independently selected from hydrogen, halogen, alkyl, trifluoromethyl, hydroxyl, alkoxy, formyloxy, alkylcarbonyloxy, hydroxyalkyl, aldehydo, amino, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylamino, mercapto, alkylmercapto, azido, and substituted or unsubstituted groups selected from alkylsulfinyloxy, alkylsulfonyloxy, carbamate, carbamido, alkoxycarbonyl, alkylaminocarbonyl, aminocarbonyl, and sulfonamido, R 14 is selected from hydrogen, halogen, alkyl, trifluoromethyl, hydroxyl, alkoxy, formyloxy, alkylcarbonyloxy, hydroxyalkyl, aldehydo, amino, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylamino, mercapto, azido, and substituted or unsubstituted groups selected from alkylsulfinyloxy, alkylsulfonyloxy, carbamate, carbamido, alkoxycarbonyl, alkylaminocarbonyl, aminocarbonyl, and sulfonamido, or

any two of R 12 , R 13 , R 14 , R 15 and R 16 form an alkylenedioxy group;

X is NR′R″ where R′ is selected from trifluoromethyl, alkenyl, alkynyl, hydroxyalkyl, alkylaminoalkyl, heterocyclyl, and heterocyclylalkyl, where the heterocycle is selected from pyrrolyl, thiophenyl, and imidazolyl, and the cyclic structure of heterocyclyl and heterocyclylalkyl is optionally substituted with one or more of halo, alkyl, trifluoromethyl, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, mercapto, alkylmercapto, and carboxamido; R″ is selected from hydrogen and cyanoalkyl, or R′ and R″ together form a 7-membered, saturated or unsaturated, heterocyclic ring containing at least one nitrogen, and optionally oxygen, and the heterocyclic ring is optionally be substituted with one or more of halo, alkyl, trifluoromethyl, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, mercapto, alkylmercapto, carboxamido, aldehydo, cyano, oxo, alkylcarbonyloxy, and sulfonamido; or ;

with the proviso that when R′ is selected from heterocyclyl and heterocyclylalkyl and Y and Y′ together is double-bonded oxygen, then R 7 and R 8 are independently selected from trifluoromethyl and alkoxy.

3. The compound, prodrug, or salt of claim 2 , wherein X is NR′R″ where R′ is selected from alkylaminoalkyl, heterocyclyl, and heterocyclylalkyl where the heterocycle is selected from pyrrolyl, and thiophenyl, and the cyclic structure of heterocyclyl and heterocyclylalkyl is optionally substituted with one or more of halo, alkyl, trifluoromethyl, hydroxyl, alkoxy, amino, alkylamino, and dialkylamino; R″ is hydrogen, or R′ and R″ together form a or 7-membered, saturated or unsaturated, heterocyclic ring containing at least one nitrogen, and optionally oxygen, and the heterocyclic ring is optionally be substituted with one or more of halo, alkyl, trifluoromethyl, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, mercapto, alkylmercapto, carboxamido, aldehydo, cyano, oxo, alkylcarbonyloxy, and sulfonamido.

4. The compound, prodrug, or salt of claim 3 , wherein X is NR′R″ where R′ is selected from heterocyclyl and heterocyclylalkyl, where heterocyclyl is pyrrolyl, which is optionally substituted with one or more of halo, alkyl, trifluoromethyl, alkoxy, alkylamino and dialkylamino; and R″ is hydrogen or dialkylaminoalkyl.

5. The compound, prodrug, or salt of claim 4 , wherein X is NR′R″ where R′ is a heterocyclylalkyl selected from 2-pyrrolylmethyl and (1-methyl-1H-pyrrol-2-yl)methyl; and R″ is hydrogen.

6. The compound, prodrug, or salt of claim 1 , wherein R and R 0 are independently selected from hydrogen and hydroxyl, and R 1 , R 2 , R 3 and R 4 are independently selected from hydrogen, halogen, alkoxy, alkyl and trifluoromethyl; n is 1; R 12 , R 13 , R 15 and R 16 are independently selected from hydrogen, halogen, alkyl, trifluoromethyl, hydroxyl, alkoxy, formyloxy, alkylcarbonyloxy, hydroxyalkyl, aldehydo, amino, alkylamino, aminoalkyl, alkylaminoalkyl, dialkylamino, mercapto, azido, and substituted or unsubstituted groups selected from alkylsulfinyloxy, alkylsulfonyloxy, carbamate, carbamido, and sulfonamido, or any two of R 12 , R 13 , R 14 , R 15 and R 16 form an alkylenedioxy group.

7. The compound, prodrug, or salt of claim 1 , wherein R 2 is selected from halogen, alkoxy and alkylmercapto, R 1 and R 3 are hydrogen; and three of R 12 , R 13 , R 15 and R 16 are independently selected from hydrogen, halogen, alkyl, trifluoromethyl, alkoxy, alkylamino, alkylaminoalkyl, and dialkylamino, and R 14 is selected from hydroxyl, hydroxyalkyl, amino, alkylamino, dialkylamino, and mercapto.

8. The compound, prodrug, or salt of claim 7 , wherein R 2 is selected from halogen and alkoxy, and R 1 and R 3 are hydrogen.

9. The compound, prodrug, or salt of claim 8 , wherein R 2 is selected from fluoro and methoxy.

10. A compound, an E-isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

(Z)—N—((1H-pyrrol-2-yl)methyl)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yflacetamide(018),

(Z)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-((1-methyl-1H-pyrrol-2-yl)methyl)acetamide (019),

(Z)—N—((1H-pyrrol-2-yl)methyl)-2-(1-(4-hydroxy-3,5-dimethoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (022),

(Z)-2-(5-methoxy-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-(1-methylpyrrolidin-3-yl)acetamide (030),

(Z)-2-(5-fluoro-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-(1-methylpyrrolidin-3-yl)acetamide (031),

(Z)-2-(5-methoxy-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-(1-methylpiperidin-3-yl)acetamide (032),

(Z)-2-(5-fluoro-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-(1-methylpiperidin-3-yl)acetamide (033),

(Z)-2-(5-methoxy-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-(5-methylpyridin-3-yl)acetamide (063),

(Z)-2-(1-(4-aminocarbonyl-3,5-dimethoxybenzylidene)-5-fluoro-2-methyl-1H-inden-3-yl)-N-((1-methyl-1H-pyrrol-2-yl)methyl)acetamide (065),

(Z)-methyl 2,6-dimethoxy-4-(( 5 -methoxy-2-methyl-3-(2-((1-methylpyrrolidin-3-yl)amino)-2-oxoethyl)-1H-inden-1-ylidene)methyl)benzoate (066),

(Z)-2-(1-(3,5-dimethoxy-4-sulfamoylbenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)-N-(1-methylpyrrolidin-3-yl)acetamide (067),

(Z)-2-(1-(3,5-dimethoxy-4-ureidobenzylidene)-5-fluoro-2-methyl-1H-inden-3-yl)-N-((4-methylpyridin-3-yl)methyl)acetamide (069),

(Z)-2-(5-methoxy-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)-N-((1-methyl-1H-pyrrol-2-yl)methyl)acetamide (096),

(Z)-N-((1H-pyrrol-2-yl)methyl)-2-(5-methoxy-2-methyl-1-(3,4,5-trimethoxybenzylidene)-1H-inden-3-yl)acetamide (097),

(Z)-2-(1-(3,5-dimethoxy-4-sulfamoylbenzylidene)-5-fluoro-2-methyl- 1H-inden-3-yl)-N-((6-methylpyridin-2-yl)methyl)acetamide (098),

(Z)-4-((5-fluoro-3-(2-((furan-2-ylmethyl)amino)-2-oxoethyl)-2-methyl-1H-inden-1-ylidene)methyl)-2,6-dimethoxyphenyl(2-(dimethylamino)ethyl)carbamate (099), and

(Z)-2-(5-fluoro-1-(4-mercapto-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-((1-methyl-1H-pyrrol-2-yl)methyl)acetamide (100).

11. A compound, an E-isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from:

(Z)—N-(furan-2-ylmethyl)-2-(1-(4-hydroxy-3,5-dimethylbenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (001),

(Z)-2-(5-fluoro-1-(4-formoxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide ( 002 ),

(Z)—N-(furan-2-ylmethyl)-2-(1-(4-hydroxy-3,5-dimethoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (006),

(Z)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (007),

(Z)-N-(furan-2-ylmethyl)-2-(1-(4-hydroxy-3,5-dimethoxybenzylidene)-5,6-dimethoxy-2-methyl-1H-inden-3-yl)acetamide (008),

(Z)-N-(furan-2-ylmethyl)-2-(1-(4-hydroxy-3-methoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (012),

(Z)-2-(1-(3-bromo-4-hydroxy-5-methoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (013),

(Z)-2-(1-(3-chloro-4-hydroxy-5-methoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (014),

(Z)-2-(1-(3-fluoro-4-hydroxy-5-methoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (016),

(Z)-2-(5-fluoro-1((7-hydroxybenzo[d][1,3]dioxo1-5-yl)methylene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (017),

(Z)—N-(furan-2-ylmethyl)-2-(1-(3-hydroxy-4-methoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (020),

(Z)-2-(5-fluoro-1-(4-(hydroxymethyl)-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (021),

(Z)-N-(2-(dimethylamino)ethyl)-2-(5-fluoro-1-(furan-2-ylmethylene)-2-methyl-1H-inden-3-yl)acetamide (026),

(Z)-2-(5-fluoro-1-(4-mesyloxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (029), and

(Z)-N-(furan-2-ylmethyl)-2-(1-(4-ethoxycarbonyl-3,5-dimethoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (095).

12. A compound, an E-isomer thereof, a prodrug thereof,or a pharmaceutically acceptable salt thereof, wherein the compound is:

(Z)-2-(5-fluoro-1-(4-formoxy-3,5-dimethoxybenzylidene)-2-methyl-1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (002).

13. A compound, an E-isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is:

(Z)-N-(furan-2-ylmethyl)-2-(1-(4-hydroxy-3,5-dimethoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (006).

14. A compound, an E-isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is:

(Z)-2-(5-fluoro-1-(4-hydroxy-3,5-dimethoxybcnzylidene)-2-methyl-1H -inden-3-yl)-N-(furan-2-ylmethyl)acetamide (007).

15. A compound, an E-isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is:

(Z)-N-(furan-2-ylmethyl)-2-(1-(4-hydroxy-3-methoxybenzylidene)-5-methoxy-2-methyl-1H-inden-3-yl)acetamide (012).

16. A compound, an E-isomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt thereof, wherein the compound is:

(Z)-2-(1-(3-bromo-4-hydroxy-5-methoxybenzylidene)-5-methoxy-2-methyl -1H-inden-3-yl)-N-(furan-2-ylmethyl)acetamide (013).

17. A pharmaceutical composition comprising a compound of claim 10 , a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a compound of claim 1 , a pharmaceutically acceptable salt or prodrug thereof, optionally including at least one therapeutic agent which is not a compound of claim 6 , a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising the compound of claim 11 , a pharmaceutically acceptable salt or prodrug thereof, optionally including a therapeutic agent which is not a compound of claim 11 , and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2026
From: ADT PHARMACEUTICALS, LLC
To: PIAZZA, GARY A.; KEETON, ADAM B.; CHEN, XI; BOYD, MICHAEL R.
Reel/Frame 074310/0547 →
CHANGE OF NAME Recorded Jun 21, 2018
From: ADT PHARMACEUTICALS, INC.
To: ADT PHARMACEUTICALS, LLC
Reel/Frame 046407/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2015
From: PIAZZA, GARY A.; CHEN, XI; KEETON, ADAM B.; BOYD, MICHAEL R.
To: ADT PHARMACEUTICALS, INC.
Reel/Frame 034850/0989 →
Continuity (1)
Related Publication 20160168113A1 · Jun 16, 2016